查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012708

屍檢和病理檢測市場：按檢測類型、檢體類型、應用和最終用戶分類－2026-2032年全球市場預測

Anatomic Pathology Testing Market by Test Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，屍檢病理檢測市場價值將達到 479.2 億美元，到 2026 年將成長至 510 億美元，到 2032 年將達到 750.1 億美元，複合年成長率為 6.60%。

主要市場統計數據
基準年 2025 479.2億美元
預計年份：2026年 510億美元
預測年份 2032 750.1億美元
複合年成長率 (%) 6.60%

概述屍檢病理檢測的發展趨勢，包括技術創新、不斷變化的臨床需求、檢查室工作流程和政策因素。

屍檢病理學檢查處於臨床需求與快速技術變革的交匯點，這促使人們對診斷準確性、檢測結果報告時間以及與治療決策的整合提出了新的要求。如今，檢查室和診斷服務機構必須在分子表徵、免疫分析和影像驅動分析與傳統組織學工作流程並存的環境中運作，以支持精準醫療的發展。因此，臨床、研究和商業領域的相關人員正在重新思考投資、夥伴關係和營運流程，以應對日益複雜的臨床情況，同時控制成本並確保符合監管要求。

對正在重塑診斷流程、資料架構和檢查室人員結構的變革性技術、臨床和監管變化進行詳細檢驗。

在屍檢病理學領域，多項變革正在發生，這些變革正在改變診斷方法、檢查室工作流程以及各相關人員之間的資料流。數位病理學的應用正從試點計畫逐步過渡到許多機構的生產部署，實現了全切片成像、遠端閱片以及演算法影像分析的應用。同時，人工智慧（AI）和機器學習在常規工作流程中的廣泛應用，也對診斷演算法的檢驗、其在臨床實踐中的應用以及監管核准方面提出了新的考量。

對 2025 年美國關稅變化將如何影響供應鏈、籌資策略、試劑採購和跨境檢查室營運進行詳細分析。

2025年美國關稅政策的發展將對參與屍檢病理檢測的檢查室、製造商和經銷商產生複雜而廣泛的營運和戰略影響。短期內，由於關稅導致進口設備、試劑和耗材價格上漲，迫使採購團隊重新評估其籌資策略，增加關鍵試劑的庫存緩衝，並加快供應商合格流程，以降低供應中斷的風險。因此，採購流程現在通常會加入緊急條款、替代供應商名單和快速檢驗流程，以確保臨床服務的連續性。

透過對測試類型、檢體類別、應用程式和最終用戶的細分分析，揭示了採用趨勢、跨技術協作和優先事項。

按檢測類型分析顯示，檢查室正在建立混合診斷工作流程，將傳統組織學方法與新興的數位和分子診斷技術結合。數位病理學領域正增加對影像分析軟體和切片掃描儀的投資，以實現遠端閱片和高階形態計量分析，而蘇木精-伊紅染色仍是組織評估的基礎技術。免疫組織化學在診斷和預測性檢測中的作用不斷擴大，檢查室正根據檢測特異性和供應可靠性比較單株抗體和多株抗體策略。分子病理學已成為組織學的核心補充領域。診斷方案結合了螢光原位雜合反應、次世代定序和聚合酵素鏈鎖反應(PCR) 等技術，以捕捉基因組變異和可操作的生物標記。高碘酸雪夫染色、銀染和三色染色等特殊染色技術在區分特定診斷和疾病形態方面繼續發揮至關重要的作用。

對美洲、歐洲、中東和非洲以及亞太地區的基礎設施、償還、人才和創新採納的區域性見解。

區域趨勢對解剖病理檢測技術的應用、部署和運作有顯著影響。在美洲，臨床檢查室和研究機構受益於穩健的資本市場和完善的報銷機制，加速了數位病理平台和複雜分子檢測的早期應用。隨著醫療服務提供者從都市區醫療中心轉向區域核心實驗室，他們往往優先考慮與腫瘤診療路徑的整合以及與專業檢測中心的合作。

對儀器、試劑和軟體公司的競爭策略、創新管道、夥伴關係模式和投資重點進行詳細分析。

該行業的企業發展趨勢反映了產品專業化、垂直整合和夥伴關係主導擴張的融合。儀器製造商持續投資於自動化和互通性，設計能夠與影像分析軟體和實驗室資訊系統整合的玻片掃描器和檢測平台。試劑和抗體供應商透過平衡專有配方和廣泛的分銷策略，降低臨床檢查室的單一來源風險，專注於豐富的產品系列和穩定的供應。軟體供應商則透過檢驗的演算法、擴充性的雲端架構和以用戶為中心的介面來脫穎而出，這些產品和服務支援從常規診斷工作流程到高級研究應用的各種場景。

為檢查室管理者、技術開發人員和政策制定者提供實用建議，以加速臨床應用、改善營運和增強供應韌性。

檢查室負責人應優先考慮數位轉型策略，該戰略應從概念驗證(PoC) 實施開始，並基於明確的檢驗方案逐步推進至全面運作。從遠端二次影像判讀或大規模腫瘤病例討論會等具體用例入手，有助於機構展示臨床效用，完善與資訊系統的整合，並在開展更大規模部署之前建立組織信心。同時，採購團隊應實施供應商多元化和合格框架，以減少對單一試劑和組件供應商的依賴。這將有助於即使在地緣政治因素或關稅波動的情況下也能維持營運的連續性。

對為確保嚴謹性而採用的調查方法進行簡要說明，包括多源資料收集、專家訪談、證據檢驗驗證和分析安全措施。

本研究採用混合方法，強調檢驗和透明度。首先，透過對同儕審查文獻、監管指導文件、已發表的臨床研究和公開文件的二次分析，建構了背景基礎。然後，透過對實驗室負責人、病理科主任、採購主管、技術開發人員和臨床終端用戶進行結構化訪談等一手定性研究，補充了這些資訊來源，以揭示實際操作情況、檢驗實踐和戰略重點。

我們提供綜合分析，將技術進步、臨床需求、監管壓力和營運應對措施聯繫起來，從而得出結論並指南相關人員。

總之，解剖病理學生態系統正處於一個關鍵的十字路口，技術能力與不斷變化的臨床需求在此交會。數位病理學、先進的免疫組織化學技術和不斷擴展的分子診斷技術能夠實現更準確、更具指導意義的診斷，但同時，它們也需要協調一致的整合、檢驗和人才培養策略。監管政策的變化和產業趨勢進一步強化了這種環境，在這種環境中，韌性、適應性和實證實踐是決定競爭優勢和營運差異化的關鍵因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：解剖病理學檢測市場：依檢測類型分類

  • 數位病理學
    • 影像分析軟體
    • 幻燈片掃描儀
  • 蘇木精-伊紅染色
  • 免疫組織化學
    • 單株抗體
    • 多株抗體
  • 分子病理學
    • 螢光原位雜合反應
    • 次世代定序
    • 聚合酵素鏈鎖反應
  • 特殊染色
    • 用高碘酸鹽進行希夫染色
    • 銀染料
    • 三色染色

第9章：屍檢和病理檢測市場：檢體類型

  • 細胞學檢體
  • 冰凍切片
  • 組織切片檢查

第10章：屍檢和病理檢測市場：按應用領域分類

  • 遺傳性疾病
    • 染色體異常
    • 單基因疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 攝護腺癌

第11章：屍檢和病理檢測市場：按最終用戶分類

  • 診斷檢查室
  • 醫院
  • 研究機構

第12章：屍檢和病理檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：屍檢病理檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：屍檢和病理檢測市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：屍檢和病理檢測市場

第16章 中國：屍檢和病理檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abcam plc
  • Agilent Technologies Inc.
  • Becton, Dickinson and Company
  • BioGenex Laboratories Inc.
  • Bio SB Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche AG
  • Hamamatsu Photonics KK
  • Hologic Inc.
  • Indica Labs LLC
  • Laboratory Corporation of America Holdings
  • Leica Biosystems
  • Merck KGaA
  • NeoGenomics Laboratories Inc.
  • PerkinElmer Inc.
  • Philips Healthcare
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Sakura Finetek USA Inc.
  • Sonic Healthcare Limited
  • Synlab Holding GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901066173

The Anatomic Pathology Testing Market was valued at USD 47.92 billion in 2025 and is projected to grow to USD 51.00 billion in 2026, with a CAGR of 6.60%, reaching USD 75.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.92 billion
Estimated Year [2026] USD 51.00 billion
Forecast Year [2032] USD 75.01 billion
CAGR (%) 6.60%

An introductory overview of anatomic pathology testing trends integrating technological innovation, clinical demand shifts, laboratory workflows, policy drivers

Anatomic pathology testing stands at the intersection of clinical necessity and rapid technological change, driving new expectations for diagnostic accuracy, turnaround time, and integration with therapeutic decision-making. Laboratories and diagnostic services now operate in an environment where molecular characterization, immunoprofiling and image-driven analytics must co-exist with traditional histology workflows to support precision medicine pathways. Consequently, stakeholders across clinical, research and commercial settings are recalibrating investments, partnerships and operational processes to meet rising clinical complexity while controlling costs and ensuring regulatory compliance.

Furthermore, shifts in healthcare delivery-from outpatient oncology programs to centralized reference labs-have altered specimen flows, testing volumes and the locus of diagnostic decision-making. As a result, laboratory leaders are evaluating digital and molecular toolsets not only for their diagnostic value but for their ability to integrate into electronic health records, laboratory information systems and multidisciplinary care teams. In light of these dynamics, the executive synthesis that follows highlights the major drivers reshaping practice, the structural challenges that require strategic response, and the practical considerations that decision-makers should weigh when prioritizing investments in people, technology and partnerships.

A detailed examination of transformative technological, clinical and regulatory shifts reshaping diagnostic pathways, data architecture and laboratory workforce

The landscape of anatomic pathology testing is undergoing several transformative shifts that are changing how diagnoses are made, how laboratories organize work, and how data flows between stakeholders. Digital pathology adoption has progressed from pilot installations to production deployments in many institutions, enabling whole slide imaging, remote review and the application of algorithmic image analysis. At the same time, the diffusion of artificial intelligence and machine learning into routine workflows has introduced new considerations around validation, clinical integration and regulatory clearance of diagnostic algorithms.

Concurrently, molecular pathology techniques such as next-generation sequencing, fluorescence in situ hybridization and targeted PCR are redefining diagnostic categories and therapeutic stratification. This molecular expansion necessitates increased collaboration between histopathology and molecular laboratories, and it elevates demands on bioinformatics, data storage and cross-discipline training. Regulatory attention and reimbursement frameworks are also evolving; as a result, laboratories must navigate changing validation expectations and value demonstration requirements. Lastly, workforce pressures, supply chain volatility and increasing demand for faster turnaround times are prompting laboratories to seek automation, streamlined workflows and strategic vendor partnerships to sustain quality and throughput. Taken together, these shifts are reshaping priorities across procurement, talent development and clinical service design.

A focused analysis of how United States tariff changes in 2025 are altering supply chains, procurement tactics, reagent sourcing and cross-border lab operations

United States tariff policy developments in 2025 have produced a complex set of operational and strategic effects for laboratories, manufacturers and distributors involved in anatomic pathology testing. In the short term, tariff-induced increases on imported instruments, reagents and consumables have compelled procurement teams to reassess sourcing strategies, increase inventory buffers for critical reagents and accelerate supplier qualification processes to reduce exposure to supply disruption. Consequently, procurement cycles now often include contingency clauses, alternative supplier lists and accelerated validation pathways to ensure continuity of clinical services.

Over the medium term, these trade measures have highlighted the economic and logistical value of supplier diversification and regionalized sourcing. Some clinical laboratories and manufacturing partners have pursued nearer-shore manufacturing partnerships, contract manufacturing expansions and localized warehousing to mitigate freight volatility and duty risk. At the same time, manufacturers are revisiting product design and bill-of-materials sourcing to reduce exposure to tariffed components, while service organizations are re-evaluating maintenance and spare parts strategies. Regulatory and contractual implications also surface when suppliers change sourcing origins; therefore, institutions must ensure that any substituted components meet the original performance and regulatory benchmarks.

Moreover, tariff-driven cost pressures can accelerate conversations around automation and assay consolidation that reduce per-test dependency on imported consumables. To manage these pressures, stakeholders increasingly emphasize scenario planning, multi-year supplier agreements with hedging provisions, and collaborative forecasting with supply partners. In sum, tariff dynamics in 2025 are prompting a strategic reorientation toward supply resilience, procurement agility and stronger industry-lab collaboration to safeguard diagnostic continuity.

Segmentation-focused insights across test types, sample categories, applications and end users revealing adoption dynamics, technology linkages and priorities

Analysis by test type reveals that laboratories are balancing legacy histology techniques with emergent digital and molecular modalities to create hybrid diagnostic workflows. Digital Pathology attracts investment in both image analysis software and slide scanners to enable remote review and advanced morphometric analysis, while Hematoxylin and Eosin staining remains the foundational tissue assessment method. Immunohistochemistry continues to expand its role for diagnostic and predictive testing, with laboratories weighing monoclonal versus polyclonal antibody strategies according to assay specificity and supply reliability. Molecular Pathology has become a core complement to histology; diagnostic portfolios blend fluorescence in situ hybridization, next-generation sequencing and polymerase chain reaction approaches to capture genomic alterations and actionable biomarkers. Special Staining techniques such as periodic acid-Schiff stain, silver stain and trichrome stain retain importance for niche diagnostic contexts and for distinguishing disease morphologies.

When sample type is considered, distinctions among cytology samples, frozen sections and tissue biopsy specimens drive differences in pre-analytic handling, turnaround expectations and instrumentation needs. These sample-specific demands in turn shape the workflows and validation strategies laboratories adopt. In terms of application, testing programs align with genetic disorder evaluation, infectious disease detection and oncology diagnostics. Genetic assessments further bifurcate into chromosomal versus single-gene disorder workflows, infectious disease testing delineates bacterial from viral pathogen detection strategies, and oncology protocols increasingly prioritize tumor-specific panels such as those used in breast, lung and prostate cancer contexts. Finally, end users including diagnostic laboratories, hospitals and research institutes have distinct procurement cycles, regulatory requirements and staffing models, all of which influence how technologies are deployed and scaled across care pathways.

Regional insight into infrastructure, reimbursement, talent and innovation adoption distinguishing the Americas, Europe, Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on the adoption, deployment and operationalization of anatomic pathology testing technologies. In the Americas, clinical and research laboratories benefit from robust capital markets and established reimbursement pathways, which facilitate early adoption of digital pathology platforms and complex molecular assays. Transitioning from urban medical centers to regional reference laboratories, providers often emphasize integration with oncology care pathways and partnerships with specialty testing centers.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement structures and infrastructure readiness leads to differentiated adoption curves. In parts of Europe, standardized healthcare systems and centralized procurement can support broad rollouts of validated digital workflows, whereas in other regions, variable funding and workforce availability necessitate more focused, incremental implementation strategies. Meanwhile, capacity-building initiatives and public-private partnerships in certain Middle East and African locales are beginning to address gaps in molecular testing and digital infrastructure.

Across Asia-Pacific, a combination of large patient volumes, rapid infrastructure investment and local manufacturing capabilities is accelerating uptake of both high-throughput molecular platforms and automated histology solutions. National strategies that prioritize precision medicine and diagnostic modernization are enabling faster integration of next-generation sequencing, slide scanning and telepathology services. Taken together, these regional patterns underline the need for adaptable deployment models and region-specific commercialization approaches to meet clinical demand and infrastructure realities.

An in-depth view of competitive strategies, innovation pipelines, partnership models and investment priorities among instrumentation, reagent and software players

Company behavior in this sector reflects a mix of product specialization, vertical integration and partnership-driven expansion. Instrumentation manufacturers continue to invest in automation and interoperability, designing slide scanners and laboratory platforms that integrate with image analysis software and laboratory information systems. Reagent and antibody suppliers focus on portfolio breadth and supply stability, balancing proprietary formulations with wider distribution strategies to reduce single-source risk for clinical laboratories. Software vendors are differentiating through validated algorithms, scalable cloud architectures and user-centered interfaces that support routine diagnostic workflows as well as advanced research applications.

Strategic collaboration remains a hallmark of competitive positioning: partnerships among instrument makers, reagent suppliers and software developers enable bundled solutions that shorten adoption cycles and simplify validation efforts for end users. Concurrently, some organizations pursue targeted mergers and acquisitions to accelerate access to complementary capabilities such as bioinformatics, cloud infrastructure or niche assay expertise. Service and support models have grown in importance as laboratories expect robust training, remote troubleshooting and performance guarantees. Finally, firms are increasingly attentive to regulatory pathways and evidence generation, prioritizing clinical validation studies and post-market surveillance to substantiate diagnostic claims and to support payer discussions.

Actionable recommendations for laboratory leaders, technology developers and policymakers to speed clinical adoption, improve operations and boost supply resilience

Laboratory leaders should prioritize a phased digital adoption strategy that begins with proof-of-concept deployments and progresses to scaled production under clear validation protocols. By starting with targeted use cases-such as remote secondary reads or high-volume tumor boards-organizations can demonstrate clinical utility, refine integration with information systems and build institutional confidence before committing to broader rollouts. In parallel, procurement teams should implement supplier diversification and qualification frameworks that reduce reliance on single-source reagents and parts; this will preserve operational continuity in the face of geopolitical or tariff-driven disruption.

Technology developers must invest in interoperable designs and open standards to ease integration with laboratory information systems and electronic health records, thereby lowering the barrier to clinical adoption. Regulatory engagement and transparent performance documentation are essential; developers should pursue rigorous clinical validation and publish peer-reviewed evidence that supports real-world use. Policy makers and payers can accelerate value realization by supporting pilot reimbursement schemes for clinically validated digital and molecular assays that demonstrably improve diagnostic accuracy or patient management.

Finally, workforce planning should combine targeted upskilling with role redesign: pathologists, histotechnologists and molecular specialists require training on new platforms, while organizations should create cross-functional teams that align laboratory scientists, data engineers and clinical stakeholders to operationalize insights into care pathways. These integrated actions will strengthen resilience, optimize resource allocation and enable sustainable adoption.

A concise methodology describing multi-source data collection, expert interviews, evidence triangulation and analytical safeguards applied to ensure rigor

This research applies a mixed-methods approach that emphasizes triangulation and transparency. Secondary analysis of peer-reviewed literature, regulatory guidance documents, published clinical studies and public filings established the contextual foundation. These sources were then augmented by primary qualitative research, including structured interviews with laboratory directors, heads of pathology, procurement executives, technology developers and clinical end users to surface operational realities, validation practices and strategic priorities.

Analytical safeguards included cross-validation of claims against regulatory approvals and published clinical evidence, as well as scenario-based sensitivity checks for operational variables such as turnaround requirements and reagent lead times. Data integrity processes encompassed interview transcription verification, thematic coding to identify convergent insights, and methodical documentation of assumptions and inclusion criteria. Limitations are acknowledged: while primary interviews spanned diverse geographies and institutional profiles, some regional nuance may vary by local policy and reimbursement contexts. Ethical considerations guided the work throughout; interview participants provided informed consent and proprietary information was handled under confidentiality protocols. Together, these methods support a rigorous and auditable synthesis intended to inform practical decision-making.

A concluding synthesis linking technological advances, clinical imperatives, regulatory pressures and operational responses to provide guidance for stakeholders

In conclusion, the anatomic pathology testing ecosystem is at a pivotal juncture where technological capability meets evolving clinical expectations. Digital pathology, advanced immunohistochemistry approaches and expanding molecular diagnostics collectively enable more precise, actionable diagnoses, but they also demand cohesive strategies for integration, validation and workforce development. Regulatory shifts and trade dynamics further contribute to an environment where resilience, adaptability and evidence generation are decisive competitive and operational differentiators.

Therefore, stakeholders should pursue pragmatic, staged adoption pathways, strengthen supplier relationships and invest in interoperable systems that reduce friction across diagnostic workflows. By aligning clinical objectives with robust validation and data governance practices, laboratories can translate technological potential into measurable improvements in diagnostic quality and care coordination. Ultimately, the organizations that balance clinical rigor, operational efficiency and strategic partnerships will be best positioned to deliver sustainable diagnostic value in service of patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anatomic Pathology Testing Market, by Test Type

  • 8.1. Digital Pathology
    • 8.1.1. Image Analysis Software
    • 8.1.2. Slide Scanners
  • 8.2. Hematoxylin And Eosin Staining
  • 8.3. Immunohistochemistry
    • 8.3.1. Monoclonal Antibody
    • 8.3.2. Polyclonal Antibody
  • 8.4. Molecular Pathology
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction
  • 8.5. Special Staining
    • 8.5.1. Periodic Acid-Schiff Stain
    • 8.5.2. Silver Stain
    • 8.5.3. Trichrome Stain

9. Anatomic Pathology Testing Market, by Sample Type

  • 9.1. Cytology Samples
  • 9.2. Frozen Sections
  • 9.3. Tissue Biopsy

10. Anatomic Pathology Testing Market, by Application

  • 10.1. Genetic Disorders
    • 10.1.1. Chromosomal Disorders
    • 10.1.2. Single Gene Disorders
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial Infections
    • 10.2.2. Viral Infections
  • 10.3. Oncology
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Prostate Cancer

11. Anatomic Pathology Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Anatomic Pathology Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anatomic Pathology Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anatomic Pathology Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anatomic Pathology Testing Market

16. China Anatomic Pathology Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abcam plc
  • 17.7. Agilent Technologies Inc.
  • 17.8. Becton, Dickinson and Company
  • 17.9. BioGenex Laboratories Inc.
  • 17.10. Bio SB Inc.
  • 17.11. Danaher Corporation
  • 17.12. Eurofins Scientific SE
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Hamamatsu Photonics K.K.
  • 17.15. Hologic Inc.
  • 17.16. Indica Labs LLC
  • 17.17. Laboratory Corporation of America Holdings
  • 17.18. Leica Biosystems
  • 17.19. Merck KGaA
  • 17.20. NeoGenomics Laboratories Inc.
  • 17.21. PerkinElmer Inc.
  • 17.22. Philips Healthcare
  • 17.23. Qiagen N.V.
  • 17.24. Quest Diagnostics Incorporated
  • 17.25. Sakura Finetek USA Inc.
  • 17.26. Sonic Healthcare Limited
  • 17.27. Synlab Holding GmbH
  • 17.28. Sysmex Corporation
  • 17.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)